Overview

Glaucoma is a leading cause of irreversible blindness, affecting an estimated 67 million people worldwide. Current methods for treating this disease are drug therapies, with a failure rate of up to 35%, and surgery, with complication rates of 20%-40%. The main reason for these potential negative outcomes is that neither of the two existing methods can achieve a personalized pressure in the eye to prevent vision loss for each patient. The Camras Shunt will provide ophthalmologists with the only treatment that predictably controls pressure to prevent blindness. In addition, the implantation of the device is simple, minimally invasive, and reduces the surgical time by approximately 50% when compared to other shunt procedures.

The market for treating glaucoma is large and growing. While the company’s addressable market in the U.S. is any glaucoma patient that is seeking treatment, it will initially focus on patients where drug therapy has failed to control eye pressure. It is estimated that by 2020, the overall surgical market in the U.S. will be 336,000 individuals undergoing 672,000 procedures, for a market potential of $604 million. The glaucoma patient population is expected to grow by 36% in the next decade. In the last ten years, the use of shunts has increased at an annual rate of 8.8%. With the Camras Shunt’s unique capabilities, Camras Vision is well positioned to take advantage of this trend.

Camras Vision has a strong management team supported by a very experienced team of scientific and business advisors. The CEO was previously the COO at Summit Technology, the first company to bring PRK/LASIK to market, and has worked in numerous startups and has led the sale of two different companies to strategic partners.

Team

Lew Bender Intensity Therapeutics

Ray Krauss

CEO

Ray Krauss has 35+ years executive experience in the medical device industry (R&D, Business Development, Regulatory, QA and General Management). His experience includes both PMA and 510(k) devices as well as working in private & public companies, ranging from 2-person startups to 200+. He has worked in numerous startups, raised financing from Angel Investors and Venture Capital firms, and led the sale of two different companies to strategic partners. Additionally, he was COO at Summit Technology, the first company to bring PRK/LASIK to the market.

Read More Less
Lew Bender Intensity Therapeutics

Roberto Alfaro

President

Roberto Alfaro has previous experience as a Manager for Deloitte, where he acquired detailed knowledge in developing and improving operational processes, managing a multi-billion-dollar project, selling new services to clients, and managing projects domestically and internationally in Asia, Europe, and South America. His expertise lies in finance and operations development. While in graduate school at Duke University, he has consulted with start-ups in the biomedical and tech industries in operational, market and financial development. He received his B.S. from the University at Albany and his MBA from the Fuqua School of Business at Duke University.

Read More Less
Lew Bender Intensity Therapeutics

Lucinda Camras, Ph.D.

Chief Scientific Officer

Lucinda Camras has been working in aqueous humor dynamics and biomedical engineering for over 13 years. She has five patents issued or pending in the ophthalmology field and 10 peer-reviewed papers in reputable scientific journals. Dr. Camras has served as the Director of Scientific Research at ACE Vision Group, a start-up ophthalmic company going through clinical trials. She also has conducted in vitro feasibility testing of a glaucoma implant (Hydrus) that is currently in FDA trials. Dr. Camras has presented at numerous international conferences, moderated scientific sessions, and received various national and institutional awards. She graduated from Northwestern University with a B.S. in biomedical engineering and from Duke University with a Ph.D. in biomedical engineering.

Read More Less
Lew Bender Intensity Therapeutics

Sanjay Asrani, M.D.

Interim Chief Medical Officer & Clinical Advisor

Dr. Asrani has been practicing glaucoma surgery at the Duke Eye Center for the past 10 years and has implanted over 500 glaucoma drainage devices in patients. He has played a significant role in the development of a new modified shunt in conjunction with New World Medical.

Read More Less
Register to view more